NextCure Gains FDA Fast Track for Ovarian Cancer ADC, Plans ASCO Data in June
NextCure’s SIM0505 ADC received FDA Fast Track designation for platinum-resistant ovarian cancer and dose optimization has begun, with Phase 1 escalation data slated for ASCO 2026. The company ended Q1 with $29.7 million in cash, sufficient to fund operations through proof-of-concept in the first half of 2027.
1. Clinical and Regulatory Milestones
SIM0505, NextCure’s cadherin-6 ADC for platinum-resistant ovarian cancer, secured FDA Fast Track designation and initiated a Phase 1 dose optimization study in gynecologic cancers this month. Initial dose escalation results from U.S. and China cohorts are expected at ASCO 2026 on June 1, and site expansion is planned for Canada and Europe in the second half of 2026.
2. LNCB74 Phase 1 Trial Progress
LNCB74, NextCure’s B7-H4-targeted ADC, continues open-label Phase 1 dose escalation in breast, gynecologic and adenoid cystic carcinoma patients. The company will update on enrollment and dose-level findings in the second half of 2026 as it refines dosing schedules within the anticipated therapeutic window.
3. Q1 Financial Results and Cash Runway
NextCure reported $29.7 million in cash, cash equivalents and marketable securities at March 31, down from $41.8 million at year-end 2025, reflecting $13.4 million used in operations. R&D expenses fell to $6.8 million and G&A to $3.3 million, driving a net loss of $9.8 million and extending funding into mid-2027 through proof-of-concept for SIM0505.